Vial labeled IGF 1 LR3 on a laboratory table with a scientist analyzing metabolic health data on a screen in the background, representing peptide research for muscle growth and metabolic support.

Peptides are increasingly recognized for their promising therapeutic potential, and one peptide that has attracted considerable interest is Insulin-like Growth Factor 1 Long R3 (IGF-1 LR3). Known for its roles in muscle development and repair, bone growth, and wound healing, IGF-1 LR3 stands out due to its distinct properties. This peptide has become a focal point in medical research and sports performance enhancement.

What is IGF-1 LR3 ‎ ‎

IGF-1 LR3, also known as Insulin-like Growth Factor 1 Long R3, is a synthetic peptide involved in metabolism and muscle development. This modified version of the endogenous insulin-like growth factor (IGF-1) has glutamic acid removed from position 3 and arginine added. These changes give it a longer half-life and increased stability, making it a useful tool for modifying metabolic pathways and promoting muscle development. IGF-1 LR3 is well recognized for its major effect on the differentiation and proliferation of muscle cells, which can result in noticeable increases in muscle mass. It also affects the metabolism of fat and glucose, improving metabolic health and body composition. [1] [2]

While both IGF-1 LR3 and natural IGF-1 are derived from insulin-like growth factor 1, the synthetic IGF-1 LR3 has a notable advantage. IGF-1 LR3’s half-life and binding affinity to the IGF-1 receptor are increased by the addition of arginine and the modification of the third amino acid. Compared to natural IGF-1, which is generated in the liver in response to growth hormone and is necessary for cell development and regeneration, this has more noticeable anabolic benefits. [2]

Mechanism of Action ‎ ‎

IGF-1 LR3 operates through complex interactions with cellular receptors, influencing metabolism and various physiological processes.

IGF-1 LR3 regulates muscle growth by activating key signaling pathways, such as PI3K/Akt/mTOR and PI3K/Akt/GSK3β. This leads to increased protein synthesis, improved glucose uptake, and a positive nitrogen balance, which are all essential for muscle hypertrophy. Unlike natural IGF-1, which affects nearly all cells, IGF-1 LR3 has a more pronounced impact on muscle cells, making it highly effective. [3]

It also has an important role in protein synthesis which is important for muscle growth and tissue repair, contributing to increased muscle mass and improved tissue regeneration. Additionally, IGF-1 LR3’s effects extend to enhancing bone density and potentially offering anti-aging benefits, impacting overall physiological health. ‎ ‎[3]

Benefits of IGF-1 LR3

IGF-1 LR3 provides numerous benefits for the body, such as improving overall health, improving muscle mass, and enhancing various physiological functions. Here are some of the most notable benefits of IGF-1 LR3:

Muscle Hypertrophy

IGF-1 LR3 promotes an increased rate of cell proliferation and division, or hyperplasia, by remaining in the bloodstream for a longer period compared to regular IGF-1. This prolonged presence enhances the growth of muscle cells. [4]

In addition to its role in muscle cell proliferation, IGF-1 LR3 functions as a myostatin inhibitor. This action helps to prevent muscle breakdown and maintain strength, particularly in individuals experiencing muscle wasting. The peptide also activates a protein known as MyoD, which plays a key role in stimulating muscle hypertrophy. [5] [6]

Muscle Healing

Another important benefit of insulin-like growth factor-1 (IGF-1) is its effect on muscle regeneration. In studies with mouse models, administering human recombinant IGF-1 at various intervals post-injury demonstrated enhanced healing in muscles affected by lacerations, contusions, and strains. [7]

Human trials have echoed these findings, showing that direct injections of recombinant growth factors like IGF-1 can improve muscle performance and recovery after a strain injury, even 15 days following the injury. Improvements were observed in muscle strength, including both tetanic and fast-twitch capabilities, and there was a significant increase in the number and diameter of regenerating myofibers at the site of treatment. [8]

Research indicates that IGF-1 treatment can help older adults better preserve lean muscle mass, countering the effects of muscle wasting associated with aging. Sarcopenia, or age-related muscle mass loss, becomes more prevalent in elderly individuals due to decreased regenerative capacity with age, and IGF1 LR3 may be beneficial for treating such conditions. [9]

Bone Health

Clinical trials have demonstrated that IGF-1 LR3 promotes bone formation through its direct effects on osteoblasts and exhibits significant anabolic and bone-protective properties. Research has found that elevated IGF-1 levels are associated with increased bone mineral density (BMD) in older women. Additionally, combining growth hormone (GH) with IGF-1 has been shown to enhance BMD in adults, optimize peak bone acquisition, and lower fracture risk associated with GH deficiency. [9]

During puberty, growth hormone and IGF-1 are essential for skeletal development. IGF-1 enhances the uptake of amino acids and nutrients, particularly collagen, which is crucial for bone growth. Studies on pubertal children have shown that higher serum levels of IGF-1 are directly related to greater bone mineral acquisition later in life. [10]

Can IGF-1 LR3 Improve Weight Loss?

Insulin-like growth factor-1 (IGF-1) is well-known for its anabolic effects, which can influence body composition by promoting protein synthesis. However, the analog IGF-1 LR3 does not seem to directly aid in fat loss. Research involving rats revealed that while IGF-1 LR3 infusion at different levels of food intake resulted in higher body weight and improved nitrogen retention, it did not conserve muscle protein. Notably, the infusion led to fat loss only in young rats, even though plasma insulin levels were reduced across all age groups. [11]

Additionally, another study found that metformin treatment in obese cancer survivors significantly reduced IGF-1 levels, which correlated with weight loss. However, this effect diminished over time. [12]

Side Effects of IGF-1 LR3

While the specific risks of IGF-1 LR3 are not fully understood due to limited research, there are general concerns related to alterations in Insulin-like Growth Factor 1 (IGF-1) levels and its binding proteins. IGF-1’s anabolic and growth-promoting properties raise the possibility of promoting tumor growth. For example, higher levels of a binding protein called IGFBP-3 have been linked to an increased risk of colorectal cancer in older men. Similarly, certain genetic variations in the IGF1 gene have been associated with a heightened risk of childhood acute lymphoblastic leukemia.

Regarding metabolic health, elevated IGFBP-3 levels may increase the risk of type 2 diabetes mellitus (T2DM), independent of IGF-1 levels. Both excessively low and high levels of IGF-1 have also been linked to a greater risk of developing diabetes.

In terms of cardiovascular health, higher levels of IGFBP-1 and lower levels of IGFBP-3 have been found to predict increased overall and cardiovascular-related mortality in older men.

These risks are related to IGF-1 and its binding proteins, rather than specifically to IGF-1 LR3. Further research is needed to clarify the unique risks associated with IGF-1 LR3. Some of the reported direct side effects of IGF-1 LR3 include hypoglycemia, joint pain, and the risk of unintended organ growth if not carefully regulated.

The Dosage

Proper usage of IGF-1 LR3 requires careful attention to dosage and cycling. It’s recommended to begin with a smaller dose typically between 20-50mcg daily, and gradually increase by 10mcg to gauge tolerance and effectiveness. It’s best to avoid going over 75mcg daily to avoid side effects.

IGF-1 LR3 is usually administered via subcutaneous or intramuscular injections. To prevent tissue damage and ensure optimal absorption, it’s important to rotate injection sites regularly. Typically cycles last between 2 to 4 weeks, followed by a break to allow the body to recover and to avoid desensitization. It’s advisable to aim for the minimal effective dose, starting low and gradually increasing if necessary.

Stacking IGF-1 LR3

Combining IGF-1 LR3 with other compounds such as peptides, SARMs, and hormones can significantly enhance its effectiveness, offering more targeted outcomes for users.

For those focusing on anabolic growth, the IGF-1 bodybuilding dosage can be strategically adjusted when stacked with peptides, boosting muscle growth and recovery. The addition of selective androgen receptor modulators (SARMs) to the regimen may accelerate strength gains and enhance fat loss, creating a more powerful synergy.

Integrating hormones like testosterone into the stack further amplifies the anabolic effects, leading to greater overall performance enhancement. However, careful monitoring of dosages and cycle lengths is essential to avoid potential side effects or disruptions in the body’s hormonal balance.

Final Thoughts

The IGF-1 LR3 peptide has gained significant attention for its potential to promote muscle growth, and bone density, aid in weight loss, and improve overall health, making it a promising candidate for those seeking enhanced metabolic benefits.

IGF-1 LR3 is recognized for its ability to accelerate muscle recovery, stimulate protein synthesis, and increase lean body mass. This has made it particularly popular among athletes looking to enhance their performance.

Beyond muscle growth, IGF-1 LR3 has demonstrated effectiveness in improving metabolic functions, such as boosting energy levels and supporting fat loss. Its role in promoting muscle hypertrophy and preventing muscle wasting underscores its value for individuals focused on physique enhancement and overall well-being.

Sourcing

USA

USA Map Outline
  • LIMITLESS LIFE NOOTROPICS aka Biotech
  • Use Discount Code: EP20

    EP20
    COPY CODE
    Copied EP20
  • SCANTIFIX
  • Use Discount Code: Exploringpeptides

    Exploringpeptides
    COPY CODE
    Copied Exploringpeptides

Canada

Canada Map Outline
  • BIOSLAB
  • Use Discount Code: EP10

    EP10
    COPY CODE
    Copied EP10
  • SCANTIFIX
  • Use Discount Code: Exploringpeptides

    Exploringpeptides
    COPY CODE
    Copied Exploringpeptides

Europe

Europe Map Outline
  • DNLABResearch
  • Use Discount Code: EP15

    EP15
    COPY CODE
    Copied EP15
  • SCANTIFIX
  • Use Discount Code: Exploringpeptides

    Exploringpeptides
    COPY CODE
    Copied Exploringpeptides

Australia

Australia Map Outline
  • LVLUPHEALTH
  • Use Discount Code: Exploringpeptides

    Exploringpeptides
    COPY CODE
    Copied Exploringpeptides
  • SCANTIFIX
  • Use Discount Code: Exploringpeptides

    Exploringpeptides
    COPY CODE
    Copied Exploringpeptides

References

[1] Tomas, F. M., Lemmey, A. B., Read, L. C., & Ballard, F. J. (1996). Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. Journal of Endocrinology, 150(1), 77-84. Retrieved Dec 12, 2024, from https://doi.org/10.1677/joe.0.1500077

[2] Wikipedia contributors. "IGF-1 LR3." Wikipedia, The Free Encyclopedia, 19 June 2023, 23:17 UTC. Accessed 12 December 2024. https://en.wikipedia.org/w/index.php?title=IGF-1_LR3&oldid=1160989525.

[3] Yoshida, T., & Delafontaine, P. (2020). Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells, 9(9), 1970. https://doi.org/10.3390/cells9091970

[4] Lambrecht N. IGF-1/IGFBP-3 Serum Ratio as a Robust Measure to Determine GH Deficiency and Guide Human Recombinant GH Therapy. J Clin Endocrinol Metab. 2023 Mar 10;108(4):e54-e55. doi: 10.1210/clinem/dgac687. PMID: 36454697.

[5] Engert JC, Berglund EB, Rosenthal N. Proliferation precedes differentiation in IGF-I-stimulated myogenesis. J Cell Biol. 1996 Oct;135(2):431-40. doi: 10.1083/jcb.135.2.431. PMID: 8896599; PMCID: PMC2121039.

[6] Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet Muscle. 2011 Jan 24;1(1):4. doi: 10.1186/2044-5040-1-4. PMID: 21798082; PMCID: PMC3143906.

[7] Laumonier, Thomas & Menetrey, Jacques. (2016). Muscle injuries and strategies for improving their repair. Journal of Experimental Orthopaedics. 3. 10.1186/s40634-016-0051-7.

[8] Kasemkijwattana, Channarong MD*,‡; Menetrey, Jacques MD*,‡; Bosch, Patrick MD*; Somogyi, George PhD†; Moreland, Morey S. MD*; Fu, Freddie H. MD**; Buranapanitkit, Boonsin MD*; Watkins, Simon S. PhD§; Huard, Johnny PhD*. Use of Growth Factors to Improve Muscle Healing After Strain Injury. Clinical Orthopaedics and Related Research 370():p 272-285, January 2000.

[9] Cappola AR, Bandeen-Roche K, Wand GS, Volpato S, Fried LP. Association of IGF-I levels with muscle strength and mobility in older women. J Clin Endocrinol Metab. 2001 Sep;86(9):4139-46. doi: 10.1210/jcem.86.9.7868. PMID: 11549640.

[9] Locatelli, Vittorio, Bianchi, Vittorio E., Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis, International Journal of Endocrinology, 2014, 235060, 25 pages, 2014. https://doi.org/10.1155/2014/235060

[10] Kouda, K., Iki, M., Ohara, K. et al. Associations between serum levels of insulin-like growth factor-I and bone mineral acquisition in pubertal children: a 3-year follow-up study in Hamamatsu, Japan. J Physiol Anthropol 38, 16 (2019). https://doi.org/10.1186/s40101-019-0210-5

[11] Gajanandana O, Irvine K, Grant PA, Francis GL, Knowles SE, Wrin J, Wallace JC, Owens PC. Measurement of an analog of insulin-like growth factor-I in blood plasma using a novel enzyme-linked immunosorbent assay. J Endocrinol. 1998 Mar;156(3):407-14. doi: 10.1677/joe.0.1560407. PMID: 9582496.

[12] Yeh HC, Maruthur NM, Wang NY, Jerome GJ, Dalcin AT, Tseng E, White K, Miller ER, Juraschek SP, Mueller NT, Charleston J, Durkin N, Hassoon A, Lansey DG, Kanarek NF, Carducci MA, Appel LJ. Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4179-e4191. doi: 10.1210/clinem/dgab266. PMID: 33884414; PMCID: PMC8475239.